The latest Investing Matters Podcast episode with London Stock Exchange Group's Chris Mayo has just been released. Listen here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAngle Share News (AGL)

Share Price Information for Angle (AGL)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 15.25
Bid: 15.00
Ask: 15.50
Change: -0.50 (-3.23%)
Spread: 0.50 (3.333%)
Open: 15.00
High: 15.50
Low: 14.65
Prev. Close: 15.50
AGL Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Angle Appoints Cancer Diagnostic Firm Chief As Non-Executive Director

Thu, 01st Nov 2018 14:09

LONDON (Alliance News) - Biopsy company Angle PLC said Thursday it has appointed the President of Euronext-listed cancer diagnostics firm MDxHealth to its board.

Jan Groen joins the board of Angle with immediate effect as a non-executive director. His is currently president and chief executive at MDxHealth, which develops and commercialises tests to detect urological and other cancers.

Before his role at MDxHealth Inc, Groen was president of US operations and global chief operating officer of cancer diagnostics company Agendia Inc, which developed a test to predict breast cancer recurrence based on the gene expression of tumours.

In addition, Groen is also holds a non-executive board position at private Dutch company SPL Medical BV. He was previously a board member at Belgian company MyCartis NV.

Shares in Angle were up 0.6% at 41.50 pence on Thursday.

More News
31 Mar 2020 09:40

Angle UK, US, Canada operations 'severely disrupted' by Covid-19

(Sharecast News) - Liquid biopsy company Angle said on Tuesday that operations in the UK, US and Canada had all been "severely disrupted" by the Covid-19 pandemic.

Read more
3 Mar 2020 18:58

Angle Parsortix Test Used To Help Discover Brain Metastasis

Angle Parsortix Test Used To Help Discover Brain Metastasis

Read more
27 Feb 2020 14:09

Angle's Parsortix Beats Others In Assessing Kidney Cancer Patients

Angle's Parsortix Beats Others In Assessing Kidney Cancer Patients

Read more
27 Feb 2020 12:42

Angle upbeat on recent Parsortix research out of Italy

(Sharecast News) - Liquid biopsy company Angle announced on Thursday that Istituto Nazionale Tumori di Milano in Milan, Italy, has published results of work assessing the performance of its 'Parsortix' system in renal cell carcinoma (RCC), demonstrating key advantages of Parsortix.

Read more
17 Feb 2020 15:25

Angle upbeat on German research into 'Parsortix'

(Sharecast News) - Liquid biopsy company Angle announced on Monday that University Medical Centre Hamburg-Eppendorf has published results of work undertaken to assess the analytical and clinical performance of 'Parsortix' in multiple metastatic cancer types, with the main emphasis on metastatic breast cancer.

Read more
11 Feb 2020 10:51

Study Finds Angle's Parsortix Can Predict Melanoma Sufferers Survival

Study Finds Angle's Parsortix Can Predict Melanoma Sufferers Survival

Read more
11 Feb 2020 07:41

Angle upbeat on research into Parsortix with melanoma patients

(Sharecast News) - Liquid biopsy company Angle announced on Tuesday that a customer, the Edith Cowan University in Perth, Western Australia, has published results of research into the use of its 'Parsortix' system with melanoma patients.

Read more
30 Jan 2020 11:41

Angle Loss Widens As It Eyes US Parsotix Cancer Treatment Clearance

Angle Loss Widens As It Eyes US Parsotix Cancer Treatment Clearance

Read more
23 Jan 2020 16:10

UK Earnings, Trading Statements Calendar - Next 7 Days

UK Earnings, Trading Statements Calendar - Next 7 Days

Read more
22 Jan 2020 11:00

Angle Eyes US Consent For Parsortix Cancer Medication In Third Quarter

Angle Eyes US Consent For Parsortix Cancer Medication In Third Quarter

Read more
7 Nov 2019 13:50

Angle Gets Study Results Demonstrating Use Of Parsortix In Melanoma

Angle Gets Study Results Demonstrating Use Of Parsortix In Melanoma

Read more
31 Oct 2019 15:38

Angle Submits Positive Test Results For Parsortix System To US FDA

Angle Submits Positive Test Results For Parsortix System To US FDA

Read more
4 Oct 2019 15:17

Angle upbeat on patent grant for prostate cancer blood assessment

(Sharecast News) - Liquid biopsy company Angle announced on Friday that the Queen Mary University of London (QMUL) European patent covering the measurement of the number of megakaryocytes in a patient blood sample as an assessment of the prognosis for prostate cancer has been granted.

Read more
4 Oct 2019 08:58

Angle Notes Queen Mary University's European Cancer Prognosis Patent

Angle Notes Queen Mary University's European Cancer Prognosis Patent

Read more
4 Sep 2019 14:09

Angle Reports Positive Study Results For Parsortix System

(Alliance News) - Angle PLC on Wednesday noted positive results from a study of its Parsortix system in small cell lung cancer.Parsortix is Angle's liquid biopsy technology, meaning it

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.